Maria Delioukina

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Thierry Façon, Shaji Kumar, Torben Plesner et al. · The Lancet Oncology · 2021 · 363 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Mark Kirschbaum, Paul Frankel, Leslie Popplewell et al. · Journal of Clinical Oncology · 2011 · 212 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

André Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh et al. · Blood · 2019 · 134 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +12

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Youn H. Kim, Francine Foss, Jasmine Zain et al. · Blood · 2012 · 131 citations

Medicine, Oncology, Pharmacotherapy +11

Circadian function in patients with advanced non-small-cell lung cancer

R. D. Levin, M. Daehler, James F. Grutsch et al. · British Journal of Cancer · 2005 · 118 citations · Full text

Nursing, Health Sciences, Oncology +17